Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, November 3, 2011

"Preemptive" statin-myopathy gene test helps explore new world of pharmacogenomics

This might be able to tell if you can't tolerate statins due to muscle problems. no solution but a first step.








Patients considered for simvastatin therapy here at Vanderbilt University Medical Center (VUMC) will be offered a genetic screening test that can identify variants known to increase the risk of myopathy associated with the drug, the institution has announced [1].
The test, actually a panel aimed at 184 different variants on 34 genes (VeraCode ADME Core Panel, Illumina, San Diego, CA) will be used to identify patients at increased simvastatin-related myopathy risk who might better avoid the drug.
Patients will be tested as part of the VUMC program Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment (PREDICT), which is exploring the feasibility of "preemptively" including pharmacogenomic data in the electronic medical records of selected patients for possible later use in guiding treatment decisions, Dr Dan Roden (VUMC) told heartwire.
VUMC is one of a handful of institutions and the first academic medical center to have such a program, according to Roden, who is its assistant vice chancellor for personalized medicine.
The commercially available panel screens for variants known to interact with a number of commonly used drugs, including simvastatin, clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Aventis), and warfarin. PREDICT has already enrolled 3486 patients screened before they went to left-heart catheterization and who therefore had a high probability of being prescribed clopidogrel, according to Roden. Enrollments will now focus on patients who could receive simvastatin and later on patients who could get warfarin; the current overall enrollment target is 10 000 patients.

No comments:

Post a Comment